Visão geral da empresa
A clinical-stage biotechnology enterprise focused on developing molecule therapeutics designed to treat fibrosis, cancer, inflammation, and other related diseases. The company operates within the healthcare sector, specifically in the biotechnology industry, which implies a focus on research-intensive development of preclinical small molecules such as GB3226 and GB1211. Damora Therapeutics, Inc. currently holds a market capitalization of $1.73B and employs 5 individuals, while its annual revenue is listed as N/A. The market capitalization of $1.73B suggests a significant valuation relative to its stated employee count and lack of reported revenue, indicating that the company's market value is primarily derived from potential future clinical successes and intellectual property rather than current earnings or sales streams.
Saúde financeira
The company reported a net income of $-15,844,000 over the trailing twelve months, while revenue is not available and EBITDA stands at $-11,862,000. The substantial gap between the reported net income and EBITDA reveals a significant cost structure burden, likely driven by high research and development expenses typical of clinical-stage entities that cannot be offset by current sales. Free cash flow is reported at $-7,066,875, indicating that the company is burning through cash reserves to fund operations and development rather than generating liquidity from business activities. Gross margin, operating margin, and profit margin are all recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue figures are insufficient to calculate meaningful margins due to the N/A revenue status. The company holds $7.61M in cash against a total debt load of $72,000, resulting in a debt-to-equity ratio of 0.90. Despite the positive cash position relative to debt, the current debt-to-equity metric suggests a leverage profile that requires careful monitoring as the entity transitions from preclinical to clinical stages. The current ratio is 3.73, which indicates strong short-term liquidity and the ability to cover short-term obligations without immediate distress. Return on Equity is -109.5% and Return on Assets is -43.5%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic in early-stage biotechnology firms before product approval.
Avaliação de valorização
The P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is reported at -30.20. The negative forward P/E implies that analysts or market participants expect earnings to remain negative or that the company is not generating positive earnings in the foreseeable future. The price-to-book ratio is 5.71, indicating that the market values the company at a significant premium over its book value, reflecting high expectations for future asset appreciation or successful drug development. The price-to-sales ratio is N/A, and the EV/EBITDA stands at -2.33, suggesting that traditional valuation multiples are distorted by the lack of profitability and the negative earnings trajectory. The stock has traded between a 52-week low of $2.01 and a 52-week high of $38.33. Given the wide range between these two figures, the current price point represents a position with substantial volatility, potentially trading well below the 52-week high depending on the current market price. The beta value is 1.57, which indicates that the stock's price volatility is significantly higher than that of the broader market, moving 57% more than the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is N/A, and earnings growth year-over-year is also N/A due to the lack of historical revenue data and consistent profitability. Without historical revenue figures to compare, it is impossible to determine if earnings are growing faster or slower than revenue, but the absence of revenue suggests the company is in a phase where growth is measured in clinical milestones rather than top-line expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is reinvested into growth initiatives rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by a total reinvestment strategy typical of clinical-stage biotechs, where capital is directed toward advancing molecule therapeutics rather than providing income distributions.